Influence of Genetics Polymorphism of OATP2B1Transporter on Montelukast Response in Samples of Asthmatic Children

Hasnaa Haider Mohammed,Uday Abdul-Reda,Hassan Mahmood Abo-Almaali,Akeel Mahdi Hussien,Hassan Mahmood Abo-Almaali
DOI: https://doi.org/10.22317/jcms.v9i6.1449
2023-12-26
Journal of Contemporary Medical Sciences
Abstract:Background: Leukotriene receptor antagonists, such as montelukast, are an efficient substitute for inhaled corticosteroids (ICS) , which are a treatment option for mild and moderate persistent asthma.Leukotriene receptor antagonists are a class of frequently given oral asthmatic medicines.So,genetics variants that affect the intestinal OATP2B1 transporter may affect the medicinal efficacy of montelukast. Objectives: The primary objectives are to evaluate the impact of OATP2B1c.935G>A (rs12422149) genetic polymorphisms on montelukast treatment responses in children with asthma in Iraq. Methods and patients: This observational cross_sectional study was conducted from the beginning of October 2022 up to the ending of September 2023 at the respiratory clinic centre of the Karbalaa Hospital for Children.One hundred participants, both male and female, aged between six and fifteen, who had been taking montelukast as a control medication on a daily basis for at least a month, were included in the study.Following DNA extraction, allele_specific PCR was performed to identify the genotypes of the various patients. Measurements of total serum IgE, the Asthma Control Test(ACT), and the Pulmonary Function Tests (PEF and FEV1) were made. Results: Genetic amplification results indicate that the distribution of the polymorphism of the c.935G>A gene was 48% in GG wild homozygous, 45% in GA mutant heterozygous, and 7% in mutant homozygous AA. Patients with mutant genes (GA and AA) exhibit high total IgE, low PEF and FEV1, and <19 ACT scores. This polymorphism is expected to have a significant association (p value A genetic polymorphism.
What problem does this paper attempt to address?